S. Gail Eckhardt, M.D.
Dr. Eckhardt earned her medical degree from the University of Texas Medical Branch in Galveston, Texas. She completed her internship and residency in internal medicine at the University of Virginia Medical Center in Charlottesville. Her postgraduate training also includes a research fellowship at the Division of Experimental and Molecular Medicine, Scripps Clinic and Research foundation, La Jolla, California; a medical oncology fellowship at the Division of Hematology/Oncology, University of California, San Diego Hospitals, and a research fellowship, Departments of Medicine and Biology, University of California, San Diego, School of Medicine, La Jolla.

Dr. Eckhardt has served on numerous committees/study sections, including the ASCO Molecular Oncology Task Force, the EORTC Early Clinical Trials Review Panel, and the NCI Drug Development Group. She participated in the first NIH Clinical Research Roadmap initiative and in the focus group on clinical trials research. She was also Chair of the ASCO Program Committee in 2003, and Co-Chair of the first ASCO/SSO/ASTRO/AGA GI Symposium in 2004. In addition, Dr. Eckhardt is an Associate Editor of Clinical Cancer Research, and Investigational New Drugs.

Dr. Eckhardt is the Principal Investigator on three NIH grants involving early clinical trials and colorectal cancer research and has conducted numerous phase I and II clinical trials. She has published over 60 manuscripts and serves on numerous advisory boards. She is currently serving on the ASCO Board of Directors, the FDA Oncology Drugs Advisory Committee, and the NCI Developmental Therapeutics Study Section. Her area of interest is in the preclinical and clinical development of combinations of molecularly targeted compounds, with a laboratory focus on colorectal cancer.

Current laboratory projects include investigation of the molecular and therapeutic implications of the VEGFR3 receptor in colorectal and pancreatic cancer, assessment of the use of novel targeted agents as chemopotentiators in colorectal cancer, and reversal of chemotherapy resistance by mek-1 inhibitors.

Patrick J. Flynn, M.D.
Dr. Flynn received his medical degree from the University of Minnesota Medical School. He completed residency in Internal Medicine at Hennepin County Medical Center, and a Hematology/Oncology fellowship at the University of Minnesota Department of Medicine. Dr. Flynn is Board Certified in Internal Medicine, with subspecialties in Oncology and Hematology.

Carlos Gómez, M.D.
Dr. Carlos Gómez is currently Assistant Professor and Attending Physician at the University Hospital "12 de Octubre", Madrid, Spain. He has previous experience as Associate investigator at the Inmunohystochemistry, Genetics and Biochemistry Department, Vigo University, Spain, and as Clinical Trial Coordinator at the University Hospital "12 de Octubre", Madrid, Spain. His clinical research is focused on gastrointestinal malignancies, in particular pancreatic and biliary tract carcinoma. He has published 15 manuscripts and nine book chapters.

Haiyong Han, PhD
Dr. Han is an Associate Investigator for the Pancreatic Cancer Research Program in the Translational Drug Development Division of TGen. His research at TGen involves the identification of frequent alterations responsible for driving the onset and progression of pancreatic cancer and the development of new anti-pancreatic cancer agents that target these alterations. He has received the AACR-AFLAC Scholar in Cancer Research and the AACR Scholar-in-Training Awards from the American Association for Cancer Research. He has been involved in pancreatic target research with both the American Cancer Society and National Cancer Institute. Dr. Han has written many peer-reviewed gene and cancer publications including "Identification of Genes Differentially Expressed in Pancreatic Cancer Cells Using cDNA Microarray".

Jules Harris, MD
Dr. Harris has been at Rush University Medical Center since 1978 and now holds the position of Judd and Marjorie Weinberg Presidential Professor of Medicine. He had previously served as the Director of the Section of Medical Oncology of the University and Director of the University's Cancer Center. He had also served as the Associate Director of Clinical Trials and Investigation of the Illinois Cancer Council, the Comprehensive Cancer Center for the State of Illinois. He has been the Chairman of the Immunological Devices Panel of the Food and Drug Administration. He was the Principal Investigator for the NCI-SUPPORTED Rush University Medical Center membership in the Eastern Cooperative Oncology Group. He has served on numerous NCI grant review panels including that of the NCI Specialized Programs of Research Excellence (SPOREs) in the Gastrointestinal and Prostate Cancer. He is a member of the American Society of Clinical Oncology Tumor Marker Advisory Panel. Most recently, he has held an appointment as a Scientific Reviewer, Scientific Peer Review and Special Program of Research Excellence in Breast Cancer for the Department of Defense. He has written numerous original papers, book and reviews on cancer clinical trials, tumor biology and tumor immunobiology. His work includes clinical trials in pancreatic cancer and the study of immune function in pancreatic cancer patients and the effect of chemotherapy on immune function in these patients. Dr. Harris is the recipient of the Maimonides of the Israel Cancer Research Fund.